GlassScriptPhysician profile
Silviu Burcescu
NPI 1316984032
$3,194.35
in general payments reported to CMS, 2019-2025
15 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $501 · 2021: $570 · 2022: $752 · 2023: $745 · 2024: $139 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $955.30 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $746.94 | 2019-2024 | Fanapt, Hetlioz |
| Allergan, INC. | $471.07 | 2019-2020 | |
| Alkermes, INC. | $242.79 | 2021-2023 | Aristada, Lybalvi |
| Orexo US, INC. | $192.64 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $140.31 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.92 | 2020-2022 | |
| Bausch Health US, LLC | $119.22 | 2022 | |
| Neurocrine Biosciences, INC. | $75.44 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $26.11 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.21 | 2020 | |
| Neuronetics, INC. | $22.52 | 2019 | |
| Avanir Pharmaceuticals, INC. | $22.10 | 2022 | |
| Corium, LLC | $21.59 | 2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silviu Burcescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.